Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 508-516

  Patel, Kashyap ^a   Batty, Kevin T ^b,c   Moore, Brioni R ^d   Gibbons, Peter L ^b,e   Bulitta, Jürgen B ^a   Kirkpatrick, Carl M ^a  

^a MONASH UNIVERSITY   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROARTEMISININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; ERYTHROCYTE; IC 50; LIFE CYCLE; MALE; MEROZOITE; MICROBIAL GROWTH; MICROVASCULATURE; MOUSE; NONHUMAN; PARASITEMIA; PHARMACODYNAMICS; PRIORITY JOURNAL; RODENT MALARIA; SINGLE DRUG DOSE; TROPHOZOITE;

ANIMALS; ANTIMALARIALS; ARTEMISININS; BIOLOGICAL AVAILABILITY; ERYTHROCYTES; LIFE CYCLE STAGES; MALARIA; MALE; MICE; MODELS, BIOLOGICAL; PARASITEMIA; PLASMODIUM BERGHEI;

EID: 84872009554     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01463-12     Document Type: Article

References (55)

1. WHO. 2011. Global malaria programme: world malaria report 2011. World Health Organization, Geneva, Switzerland.
2. WHO. 2011. Guidelines for the treatment of malaria, 2nd ed. World Health Organization, Geneva, Switzerland.
3. Davis T, Karunajeewa H, Ilett K. 2005. Artemisinin-based combination therapies for uncomplicated malaria. Med. J. Aust. 182:181-185.
4. Ilett KF, Batty KT. 2005. Artemisinin and its derivatives, p 981-1002. In Yu VL, Edwards G, McKinnon P, Peloquin C, Morse GD (ed), Antimicrobial therapy and vaccines, vol 2. ESun Technologies, Pittsburgh, PA.
5. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
6. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359:2619-2620.
7. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, Ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F. 2012. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379:1960-1966.
8. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. 2004. Artesunate combinations for treatment of malaria: metaanalysis. Lancet 363:9-17.
9. Winter K, Hastings IM. 2011. Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure. Antimicrob. Agents Chemother. 55:3380-3392.
10. Mackenstedt U, Brockelman CR, Mehlhorn H, Raether W. 1989. Comparative morphology of human and animal malaria parasites. Parasitol. Res. 75:528-535.
11. Langhorne J, Buffet P, Galinski M, Good M, Harty J, Leroy D, Mota MM, Pasini E, Renia L, Riley E, Stins M, Duffy P. 2011. The relevance of non-human primate and rodent malaria models for humans. Malar. J. 10:23.
12. Peters W, Robinson BL. 1999. Malaria, p 757-773. In Zak O, Sande MA (ed), Handbook of animal models of infection. Academic Press, San Diego, CA.
13. Janse C, Waters A. 2002. The Plasmodium berghei research model of malaria. Leiden University Medical Centre (Leiden University Malaria Research Group (LMRG), Leiden, The Netherlands. https://www.lumc.nl/con/1040/ 81028091348221/810281121192556/811070740182556/.
14. Gibbons PL, Batty KT, Barrett PH, Davis TM, Ilett KF. 2007. Development of a pharmacodynamic model of murine malaria and antimalarial treatment with dihydroartemisinin. Int. J. Parasitol. 37:1569-1576.
15. Moore BR, Jago JD, Batty KT. 2008. Plasmodium berghei: parasite clearance after treatment with dihydroartemisinin in an asplenic murine malaria model. Exp. Parasitol. 118:458-467.
16. Moore BR, Page-Sharp M, Stoney JR, Ilett KF, Jago JD, Batty KT. 2011. Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. Antimicrob. Agents Chemother. 55:3899-3907.
17. Moore BR, Ilett KF, Page-Sharp M, Jago JD, Batty KT. 2009. Piperaquine pharmacodynamics and parasite viability in a murine malaria model. Antimicrob. Agents Chemother. 53:2707-2713.
18. Al-Sallami HS, Pavan Kumar VV, Landersdorfer CB, Bulitta JB, Duffull SB. 2009. The time course of drug effects. Pharm. Stat. 8:176-185.
19. Chan PL, Holford NH. 2001. Drug treatment effects on disease progression. Annu. Rev. Pharmacol. Toxicol. 41:625-659.
20. Landersdorfer CB, He YL, Jusko WJ. 2012. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. Br. J. Clin. Pharmacol. 73:373-390.
21. Gordi T, Xie R, Jusko WJ. 2005. Semi-mechanistic pharmacokinetic/ pharmacodynamic modelling of the antimalarial effect of artemisinin. Br. J. Clin. Pharmacol. 60:594-604.
22. Austin DJ, White NJ, Anderson RM. 1998. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J. Theor. Biol. 194:313-339.
23. Hoshen MB, Stein WD, Ginsburg H. 2002. Mathematical modelling of malaria chemotherapy: combining artesunate and mefloquine. Parasitology 124:9-15.
24. Hoshen MB, Stein WD, Ginsburg H. 1998. Modelling the chloroquine chemotherapy of falciparum malaria: the value of spacing a split dose. Parasitology 116:407-416.
25. Simpson JA, Watkins ER, Price RN, Aarons L, Kyle DE, White NJ. 2000. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob. Agents Chemother. 44:3414-3424.
26. Hoshen MB, Heinrich R, Stein WD, Ginsburg H. 2000. Mathematical modelling of the within-host dynamics of Plasmodium falciparum. Parasitology 121:227-235.
27. Metcalf CJ, Graham AL, Huijben S, Barclay VC, Long GH, Grenfell BT, Read AF, Bjørnstad ON. 2011. Partitioning regulatory mechanisms of within-host malaria dynamics using the effective propagation number. Science 333:984-988.
28. Batty KT, Gibbons PL, Davis TM, Ilett KF. 2008. Pharmacokinetics of dihydroartemisinin in a murine malaria model. Am. J. Trop. Med. Hyg. 78:641-642.
29. Batty KT, Davis TM, Thu LT, Binh TQ, Anh TK, Ilett KF. 1996. Selective high-performance liquid chromatographic determination of artesunate and alpha- and beta-dihydroartemisinin in patients with falciparum malaria. J. Chromatogr. B Biomed. Appl. 677:345-350.
30. Bauer RJ. 2008. S-ADAPT/MCPEM user's guide (version 1.57). Software for pharmacokinetic, pharmacodynamic and population data analysis. Biomedical Simulations Resource, Berkeley, CA.
31. Bulitta JB, Bingölbali A, Shin BS, Landersdorfer CB. 2011. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J. 13:201-211.
32. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504.
33. Karlsson MO, Holford NH. 2008. A tutorial on visual predictive checks, abstr. 1434. http://www.page-meeting.org/default.asp?abstract=1434.
34. Parke J, Holford NH, Charles BG. 1999. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput. Methods Programs Biomed. 59:19-29.
35. Fogel BJ, Shields CE, Von Doenhoff AEJ. 1966. The osmotic fragility of erythrocytes in experimental malaria. Am. J. Trop. Med. Hyg. 15:269-275.
36. Seed TM, Brindley D, Aikawa M, Rabbege J. 1976. Plasmodium berghei: osmotic fragility of malaria parasites and mouse host erythrocytes. Exp. Parasitol. 40:380-390.
37. Black RH. 1952. The absorption of inoculated blood containing Plasmodium berghei from the peritoneal cavity of the mouse. Ann. Trop. Med. Parasitol. 46:144-149.
38. DeLoach JR, Droleskey R. 1986. Survival of murine carrier erythrocytes injected via peritoneum. Comp. Biochem. Physiol. A Comp. Physiol. 84:447-450.
39. Flessner MF, Parker RJ, Sieber SM. 1983. Peritoneal lymphatic uptake of fibrinogen and erythrocytes in the rat. Am. J. Physiol. 244:H89-H96.
40. Evans GO. 2009. Animal hematotoxicology: a practical guide for toxicologists and biomedical researchers, appendix C, p 185. CRC Press, Boca Raton, FL.
41. Cowman AF, Crabb BS. 2006. Invasion of red blood cells by malaria parasites. Cell 124:755-766.
42. Angus BJ, Chotivanich K, Udomsangpetch R, White NJ. 1997. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood 90:2037-2040.
43. Franke-Fayard B, Fonager J, Braks A, Khan SM, Janse CJ. 2010. Sequestration and tissue accumulation of human malaria parasites: can we learn anything from rodent models of malaria? PLoS Pathog. 6:e1001032. doi:10.1371/journal.ppat.1001032.
44. Rowe JA, Claessens A, Corrigan RA, Arman M. 2009. Adhesion of Plasmodium falciparum-infected erythrocytes to human cells: molecular mechanisms and therapeutic implications. Expert Rev. Mol. Med. 11:e16. doi:http://dx.doi.org/ 10.1017/S1462399409001082.
45. Wykes MN, Kay JG, Manderson A, Liu X, Brown DL, Richard DJ, Wipasa J, Jiang SH, Jones MK, Janse CJ, Waters AP, Pierce SK, Miller LH, Stow JL, Good MF. 2011. Rodent blood-stage Plasmodium survive in dendritic cells that infect naive mice. Proc. Natl. Acad. Sci. U. S. A. 108:11205-11210.
46. LaCrue AN, Scheel M, Kennedy K, Kumar N, Kyle DE. 2011. Effects of artesunate on parasite recrudescence and dormancy in the rodent malaria model Plasmodium vinckei. PLoS One 6:e26689. doi:10.1371/journal.pone.0026689.
47. Nakazawa S. 2005. Plasmodium berghei NK65: studies on the effect of treatment duration and inoculum size on recrudescence. Exp. Parasitol. 111:59-63.
48. Teuscher F, Gatton ML, Chen N, Peters J, Kyle DE, Cheng Q. 2010. Artemisinin-induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J. Infect. Dis. 202:1362-1368.
49. Haynes RK, Cheu KW, Tang MM, Chen MJ, Guo ZF, Guo ZH, Coghi P, Monti D. 2011. Reactions of antimalarial peroxides with each of leucomethylene blue and dihydroflavins: flavin reductase and the cofactor model exemplified. ChemMedChem 6:279-291.
50. Klonis N, Crespo-Ortiz MP, Bottova I, Abu-Bakar N, Kenny S, Rosenthal P, Tilley L. 2011. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc. Natl. Acad. Sci. U. S. A. 108:11405-11410.
51. O'Neill PM, Barton VE, Ward SA. 2010. The molecular mechanism of action of artemisinin - the debate continues. Molecules 15:1705-1721.
52. Skinner TS, Manning LS, Johnston WA, Davis TM. 1996. In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int. J. Parasitol. 26:519-525.
53. Wein S, Maynadier M, Tran Van Ba C, Cerdan R, Peyrottes S, Fraisse L, Vial H. 2010. Reliability of antimalarial sensitivity tests depends on drug mechanisms of action. J. Clin. Microbiol. 48:1651-1660.
54. Batty KT, Ilett KF, Davis TM. 2004. Protein binding and alpha:beta anomer ratio of dihydroartemisinin in vivo. Br. J. Clin. Pharmacol. 57:529-533.
55. Warrell DA, Gilles HM. 2002. Essential malariology, 4th ed. Arnold, London, United Kingdom.